Connor Clark & Lunn Investment Management Ltd. Buys 11,008 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 115.8% during the third quarter, Holdings Channel.com reports. The firm owned 20,511 shares of the biopharmaceutical company’s stock after purchasing an additional 11,008 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.’s holdings in Regeneron Pharmaceuticals were worth $21,562,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Howe & Rusling Inc. grew its stake in Regeneron Pharmaceuticals by 3.4% during the 3rd quarter. Howe & Rusling Inc. now owns 462 shares of the biopharmaceutical company’s stock worth $486,000 after buying an additional 15 shares during the last quarter. Strategy Asset Managers LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $576,000. PNC Financial Services Group Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 0.8% in the third quarter. PNC Financial Services Group Inc. now owns 18,325 shares of the biopharmaceutical company’s stock worth $19,264,000 after buying an additional 153 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at $3,532,000. Finally, Fifth Third Wealth Advisors LLC raised its stake in Regeneron Pharmaceuticals by 27.0% in the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 504 shares of the biopharmaceutical company’s stock worth $530,000 after acquiring an additional 107 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on REGN. Oppenheimer cut their price objective on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. Piper Sandler dropped their price objective on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Cantor Fitzgerald restated a “neutral” rating and set a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. Evercore ISI reduced their price objective on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Finally, StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. One research analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $1,099.55.

Insiders Place Their Bets

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. This trade represents a 27.07 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 7.48% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $743.35 on Thursday. The company has a fifty day moving average of $961.76 and a two-hundred day moving average of $1,030.14. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. Regeneron Pharmaceuticals, Inc. has a 1 year low of $736.01 and a 1 year high of $1,211.20. The company has a market capitalization of $81.69 billion, a PE ratio of 18.40, a P/E/G ratio of 2.81 and a beta of 0.15.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.